| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
32,633,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
1,434,166 |
Avg
Vol: |
656,180 |
| 52
Week Range: |
$21.74 - $21.74 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2011-03-07 |
4 |
S |
$4.46 |
$941 |
D/D |
(211) |
32,169 |
|
- |
|
| D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2011-03-03 |
5 |
GD |
$0.00 |
$0 |
D/D |
17,250 |
4,613,984 |
|
- |
|
| D Ambra Constance M |
10% Owner |
– – • |
2011-03-03 |
5 |
GD |
$0.00 |
$0 |
D/D |
17,250 |
4,587,318 |
|
- |
|
| Sargent Bruce J |
Sr VP, Drug DiscoveryOfficer |
• – – |
2011-02-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
32,380 |
|
- |
|
| Henderson Lori M |
VP, general counselOfficer |
• – – |
2011-02-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,000 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2010-12-06 |
4 |
S |
$5.20 |
$10,400 |
D/D |
(2,000) |
19,988 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2010-11-14 |
4 |
S |
$5.77 |
$5,118 |
D/D |
(887) |
21,988 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2010-11-10 |
4 |
S |
$6.09 |
$2,162 |
D/D |
(355) |
22,875 |
|
- |
|
| Cable Stuart M |
10% Owner |
– – • |
2010-11-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,065,189 |
|
- |
|
| Leung Gabriel |
Director |
– • – |
2010-11-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,336 |
|
- |
|
| D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2010-08-18 |
5 |
GD |
$0.00 |
$0 |
D/D |
3,860 |
4,604,568 |
|
- |
|
| D Ambra Constance M |
10% Owner |
– – • |
2010-08-18 |
5 |
GD |
$0.00 |
$0 |
D/D |
3,860 |
4,604,568 |
|
- |
|
| Jordan Veronica Gh |
Director |
– • – |
2010-06-02 |
4 |
A |
$6.15 |
$30,000 |
D/D |
4,878 |
14,163 |
|
- |
|
| Roth Arthur J |
Director |
– • – |
2010-06-02 |
4 |
A |
$6.15 |
$12,300 |
D/D |
2,000 |
18,000 |
|
- |
|
| Ryan Una S |
Director |
– • – |
2010-06-02 |
4 |
A |
$6.15 |
$15,000 |
D/D |
2,439 |
10,899 |
|
- |
|
| Oconnor Kevin |
Director |
– • – |
2010-06-02 |
4 |
A |
$6.15 |
$15,000 |
D/D |
2,439 |
14,462 |
|
- |
|
| Anderson Paul S |
Director |
– • – |
2010-06-02 |
4 |
A |
$6.15 |
$15,000 |
D/D |
2,439 |
10,435 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2010-03-09 |
4/A |
S |
$8.83 |
$2,287 |
D/D |
(259) |
23,230 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2010-03-09 |
4 |
S |
$8.83 |
$2,287 |
D/D |
(259) |
19,730 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2010-03-08 |
4 |
A |
$8.90 |
$31,150 |
D/D |
3,500 |
23,489 |
|
- |
|
| Frost Mark T |
Chief Financial Officer |
• – – |
2010-03-08 |
4 |
A |
$8.90 |
$35,600 |
D/D |
4,000 |
39,600 |
|
- |
|
| Jennings William Steven |
Senior Vice President |
• – – |
2010-03-08 |
4 |
A |
$8.90 |
$31,150 |
D/D |
3,500 |
17,000 |
|
- |
|
| D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2010-03-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,500 |
4,608,428 |
|
- |
|
| D Ambra Constance M |
10% Owner |
– – • |
2010-03-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,500 |
4,608,428 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2009-11-19 |
4 |
S |
$8.05 |
$12,075 |
D/D |
(1,500) |
19,989 |
|
- |
|
620 Records found
|
|
Page 19 of 25 |
|
|
